Influenza -- the Disease
========================

Influenza is a highly contagious respiratory disease causing symptoms ranging from headache, myalgia, malaise, sore throat, sneezing, and nasal discharge ([@B18]). Influenza virus is transmitted via virus-laden secretions propelled by coughing or sneezing from an infected person. Most influenza infections are self-limiting, lasting for one to 5 days but host factors such as age, pregnancy, and underlying medical conditions can increase the severity of illness ([@B23]). Influenza causes high global mortality and morbidity annually, with United States alone experiencing approximately 95,000--172,000 hospitalizations and 21,000--41,000 deaths annually ([@B56]). The morbidity associated with seasonal influenza has a significant economic impact due to work absenteeism and puts huge pressure on the public health system.

Influenza Antivirals
====================

To date, the neuraminidase inhibitors (NAIs) are the only licensed class of antiviral drugs effective against currently circulating influenza viruses. Zanamivir (Relenza^TM^) and oseltamivir (Tamiflu^TM^) have been licensed since 1999 while newer NAIs, such as peramivir (Rapivab^TM^) and laninamivir (Inavir^TM^), are approved in Japan, and in the case of peramivir also in South Korea, USA, and China ([@B39]; [@B15]; [@B16]). However, the therapeutic and prophylactic efficacy of NAIs against 'seasonal' influenza infection remains hotly debated ([@B41]). The continuous risks posed by the emergence of NAI-resistant viruses ([@B97]) and the pandemic potential of avian influenza viruses, such as A(H5N1) ([@B75]) and A(H7N9) ([@B35]), has sparked a major effort to develop new antivirals for human use.

Typically, investigational antivirals will first undergo *in vitro* efficacy screening, followed by *in vivo* testing in animal models to look at pharmacokinetics/pharmacodynamics (PK/PD), drug toxicity and drug effectiveness prior to clinical trials. As such, the choice of the animal model for assessing the effectiveness of these influenza antivirals becomes critical as it provides pre-clinical data that can inform the decision for progression toward clinical trials. Currently, there are a large number of influenza antivirals undergoing clinical trials, a substantial increase from the limited trials in 2000 (**Figure [1](#F1){ref-type="fig"}**). In the majority of human clinical trials of influenza antivirals, the primary endpoint used to assess the drug efficacy is the time to alleviation of clinical symptoms, such as cough, fever, sore throat, myalgia, lethargy, nasal congestion, and headaches, whereas other aspects, including the ability to reduce viral shedding, are considered secondary endpoints ([@B30]; [@B99]; [@B60]; [@B76]; [@B100]; [@B28]).

![**Overview of clinical trials of influenza antivirals in year 2000 and 2015.** Data for 2015 extracted from clinicaltrials.gov ([@B17]) using search terms: 'Influenza' and 'antivirals' and 'antivirals treatment'.](fmicb-07-00080-g001){#F1}

Animal Models in Influenza Research
===================================

Animal models of influenza infection have played an important role in the understanding of viral pathogenicity and have served as pre-clinical models for the evaluation of vaccine candidates and new therapeutics ([@B45]; [@B61]; [@B63]). To date, there are many different animal models of influenza infection, namely ferrets, mice, guinea pigs, swine, non-human primates (NHP), and more recently, zebrafish ([@B22]). The pros and cons of the different animal models of influenza to investigate disease pathogenesis, transmission, and vaccine development have been well-described in several published reviews and are summarized here in **Table [1](#T1){ref-type="table"}** ([@B9]; [@B55]; [@B61]; [@B98]; [@B20]; [@B21]).

###### 

Comparison of different animal models for influenza infection.

  Clinical symptoms                          Human   Animal model of influenza infection                                                          
  ------------------------------------------ ------- ------------------------------------- ------- -------------- --------------- --------------- --------------
  Sneezing                                   Yes     Yes                                   No      No             Yes             Not always^a^   No
  Nasal discharge                            Yes     Yes                                   No      No             Not always^a^   Not always^a^   No
  Lethargy                                   Yes     Yes                                   Yes     No             No              Not always^a^   Unknown
  Fever                                      Yes     Yes                                   No      No             Not always^a^   Not always^a^   No
  Weight loss                                Yes     Yes                                   Yes     No             Minor           Not always^a^   No
  Viral shedding                             Yes     Yes                                   Yes     Yes            Yes             Yes             Yes
  Experimental cost                          \-      Moderate                              Low     Moderate       High            High            Low
  Transmission between animals               \-      Good                                  Poor    Good           Good            Poor            Unknown
  Can infect with human influenza viruses?   \-      Yes                                   No^b^   Yes            Yes             Yes             Unknown
  A(H1N1)pdm09^c^                            \-      Yes                                   Yes     Yes            Yes             Yes             Not reported
  A(H3N2)^c^                                 \-      Yes                                   Yes     Yes            Yes             Yes             Yes
  B^c^                                       \-      Yes                                   Yes     Not reported   Yes             Yes             Not reported
  Avian origin^c^                            \-      Yes                                   Yes     Yes            Not reported    Yes             Not reported

NHP, Non-human primates.

a

Clinical symptoms vary with different influenza strains.

b

Serial passaging is required to 'adapt' the virus to replicate in majority of mouse strains.

c

Influenza virus strain/subtype that have been tested in the animal model.

Animal Models in Influenza Antiviral Studies
--------------------------------------------

Among all animal experimental models, mice are most commonly used for testing influenza antivirals mainly due to factors, such as lower experimental cost, ease of animal handling and the ability to use large numbers of animals to attain statistical power in a single experiment ([@B91]; [@B69]; [@B101]; [@B45]; [@B2]; [@B93]; [@B110]; [@B63]). To date, weight loss, mortality (lethal model) and virus titer are the commonly used determinants of antiviral drug effectiveness in mice studies. Although these measurements are informative, the usefulness of mice in antiviral studies has been largely limited by the lack of clinical symptoms following influenza infection. The absence of clinical symptoms such as fever, sneezing, nasal discharge, and nasal inflammation in mice following influenza infection limits the extrapolation of mouse data to the human scenario where alleviation of symptoms are considered as the primary endpoint in clinical trials (**Table [1](#T1){ref-type="table"}**). In contrast, the ferret is the only animal model which displays comparable clinical symptoms to that of humans following influenza infection (**Table [1](#T1){ref-type="table"}**). In view of these factors, in this review we will discuss the current progress, limitations and the future directions of using ferrets to assess antiviral effectiveness against influenza infections.

Ferret
------

Since the discovery of the susceptibility of ferrets (*Mustela putorius furo*) to influenza virus in the 1930's ([@B95]), they remain one of the best animal models of influenza infection as they exhibit many of the clinical symptoms observed in humans following influenza infection, can be directly infected with human influenza virus without prior viral adaptation, and have the ability to transmit influenza virus efficiently between one another (**Table [1](#T1){ref-type="table"}**). The susceptibility of ferrets to human influenza viruses is due to the presence of α2-6-linked terminal *N*-acetylneuraminic sialic acids (Neu5AC) in their respiratory tract which facilitates virus binding and the initiation of viral replication ([@B42]; [@B74]).

However, the use of ferrets for influenza studies has been limited by factors such as animal availability, genetic heterogeneity (out-bred) ([@B61]), the requirement of a complex husbandry facility and caging system ([@B57]; [@B21]), and a lack of immunological reagents and genetically modified mutants for immunological investigation ([@B61]; [@B21]). As a consequence, ferret experiments can be limited by small sample sizes (*n* ≤ 5) ([@B5]; [@B77]; [@B10]), where large animal-to-animal variability has resulted in the detection of non-statistically significant trends of antiviral effectiveness between the treatment groups in variables, such as weight, temperature, nasal inflammation, and virus titer ([@B89]; [@B25]; [@B79], [@B78]). Ideally, a larger number of ferrets should be used but limitations, such as high experimental cost, low animal availability, limited caging capacity and ethical constraint, typically restricts most studies to group sizes of five or less ferrets. Unlike the more commonly used animal models, such as rodents and guinea pigs, the use of larger animals for experimentation, such as ferrets, can be met with greater scrutiny by animal ethics governing bodies on aspects, such as the choice of animal, animal numbers and husbandry concerns. Only a small number of countries or regions (such as USA, UK, and Europe) have guidelines regarding the husbandry of ferrets for animal experimentation. Therefore in the absence of any local directives, animal ethics committees may rely on guidelines provided by other countries, particularly where the committee has little experience in the use of ferrets.

Despite these limitations, the use of ferrets in influenza research has increased considerably since 2008 (**Figure [2](#F2){ref-type="fig"}**). This increment was largely attributed to a global effort to better understand viruses with pandemic potential such as the avian influenza viruses A(H5N1) and A(H7N9), and the virus responsible for the 2009 pandemic, the A(H1N1)pdm09 virus ([@B26]; [@B108]; [@B8]; [@B40]; [@B59]; [@B71]; [@B4]; [@B86]; [@B111]). With the recent publication of the ferret genome ([@B83]), it is likely that the use of the ferret as a model of influenza will continue to rise.

![**The number of publications using different animal models of influenza.** Number of papers published on topics relating to influenza and mice/ferret/guinea pig from 1950 to 2013. Data tabulated by online automated yearly statistics of PubMed results (<http://dan.corlan.net/medline-trend.html>). Search terms used are 'Influenza' and 'Mice/ferret/guinea pig.'](fmicb-07-00080-g002){#F2}

To date, the ferret model has been used to investigate viral susceptibility and transmission ([@B108]; [@B59]; [@B111]), and as a preclinical model to investigate poorly understood areas such as immunological responses to influenza in young children (newly weaned ferrets) ([@B36]), impaired immunity in older individuals (aged ferrets) ([@B82]) and the treatment effectiveness of different antivirals to reduce influenza infection ([@B8]; [@B51]; [@B25]; [@B46]; [@B65]). Recently, the use of ferrets in influenza antiviral studies has extended to treatment effectiveness in an immunocompromised setting ([@B104]), the effectiveness of antiviral treatment or prophylaxis in preventing infections in secondary contacts ([@B79]) and the transmission of influenza between an infant and mother during breast-feeding ([@B81]).

There are a large number of experimental variables in a typical ferret antiviral effectiveness study that can alter the study outcome and that should be carefully considered to ensure that the most reliable data is generated. These variables are discussed in detail below and are summarized in **Figure [3](#F3){ref-type="fig"}**.

![**Overview of the three experimental considerations when assessing an antiviral in a ferret model of influenza infection.** i.n: Intranasal; i.p, intraperitoneal; i.v, intravenous; i.t, intratracheal; PK/PD, pharmacokinetics/pharmacodynamics; BAL, bronchoalveolar lavage; AUC, area under curve.](fmicb-07-00080-g003){#F3}

Inoculation of Influenza Virus in Ferrets
=========================================

The initiation of influenza infection in animal experimental models, and even in the human challenge model ([@B19]), is routinely carried out by instilling virus via the intranasal route. In general, intranasal instillation of virus is considered to be a simple procedure ([@B102]) compared to intratracheal ([@B50]; [@B104]) or ocular ([@B3]), by which ferrets can also be infected in a reproducible manner. However, the decision on which inoculation route to initiate infection can be dependent on the virus strain to be tested. For avian influenza viruses, such as A(H5N1) and A(H7N9), intratracheal instillation is preferred over direct inoculation into the lower respiratory tract of ferrets, as it is found to induce a more severe pneumonia that more closely resembles pathogenesis observed in humans, compared to intranasal inoculation which causes mild to moderate pneumonia in ferrets ([@B7]; [@B50]). For human seasonal viruses, such as influenza A(H1N1)pdm09, A(H3N2), and B viruses, intratrachel instillation has been used in only a small number of studies ([@B104]). Instead, ferrets can be effectively infected by intranasal instillation ([@B37]). However, the clinical severity of influenza infection via intranasal instillation is highly dependent on the volume of inoculum ([@B7]; [@B70]). A larger volume of inoculum (1 mL) results in the delivery of virus down into lower respiratory tract and into the lungs compared to smaller volumes (0.2 mL and 0.5 mL) which are primarily retained in the upper respiratory tract ([@B70]). As a result, ferrets intranasally infected with the larger volumes of inoculum have a more severe illness and lung histopathology compared to those infected with a smaller volume (0.2 mL) even when the same infectious titer of virus was used ([@B70]). These finding not only underscored influenza strains, inoculum route and volume to be important considerations in the ferret model of influenza infection but also highlighted the difficulties in interpreting data across studies using different inoculation protocols.

The alternatives to intranasal infection are the use of a 'natural' infection, that can be achieved by either contact ([@B87]; [@B79]) or non-contact transmission ([@B29]; [@B105]; [@B32]) of virus by exposing a naïve ferret to an infected ferret in the same or adjacent cage, or aerosolized challenge ([@B27]). Despite 'natural infection' being a more clinically relevant route of transmission, few studies have used this methodology, presumably due to the additional experimental time involved, additional ferret use, the requirement for larger cages to house multiple animals for contact transmission or a more complex caging system for non-contact transmission, and the lack of transmissibility of influenza viruses, such as avian influenza A(H5N1) and A(H7N9) ([@B108]; [@B4]) and influenza B virus ([@B43]), via the aerosol and/or contact route. Nevertheless, 'natural' infection has the clear benefit of infecting ferrets with a realistic infectious viral dose and results in viral replication kinetics that better mimic those of 'natural' influenza infections in humans (**Figure [4](#F4){ref-type="fig"}**). Unlike 'natural' infection, which relies on infected donor ferrets to transmit viruses to naïve recipients, a more standardized alternative is aerosol challenge which involves exposing naïve ferrets directly to known doses of aerosolized influenza viruses delivered by specific devices. Ferrets exposed to low aerosolized viral dose (1.5--2.2 FID~50~) have been shown to exhibit similar viral shedding kinetics and disease pathogenesis to those infected via 'natural' infection ([@B27]). In contrast to 'natural' infection, aerosol challenges eliminates the need for donor ferrets, allows ferrets to be infected with viruses with poor aerosol transmissibility, and enables the manipulation of variables, such as dose and timing of viral exposure, to achieve a more standardized way of infecting ferrets in a 'natural' fashion. However, few studies have reported using this methodology presumably due to the high cost involved in requiring specialized aerosol system and cages for such inoculation protocol.

![**Schematic representation of the viral shedding kinetics of intranasally infected (10^2^--10^3^, 10^4^--10^6^ TCID~50~ viral inoculum) ferrets, ferrets naturally infected by contact transmission via an infected donor and intranasally infected human in a challenge model ([@B31]; [@B1]).** Ferret viral data were adapted from published studies ([@B67]; [@B94]; [@B96]; [@B79], [@B78]).](fmicb-07-00080-g004){#F4}

The majority of ferret infection studies have used intranasal infections with inocula of high infectious viral titers (e.g., 10^6^ TCID~50~/PFU/EID~50~ per animal) which may result in a very large number of infectious particles infecting the nasal epithelial in a short time period ([@B59]; [@B25]; [@B44]; [@B96]; [@B82]; [@B62]). Ferrets infected with high viral inocula (10^4-6^ TCID~50~/animal) can show viral shedding kinetics where titers peak as early as 1 day post-infection (**Figure [4](#F4){ref-type="fig"}**). In contrast, ferrets infected with a lower viral inocula (10^2-3^ TCID~50~/animal) can show a more 'typical' viral shedding curve that more closely resembles a natural infection where viral titers gradually rise, peak and then fall ([@B1]; **Figure [4](#F4){ref-type="fig"}**). Although high titer viral inoculums have been used to increase the chances of infection or increase pathogenicity, several studies have shown that the initial titer of the inoculum does not correlate to disease severity in ferrets ([@B65]; [@B78]).

Influenza antivirals, such as NAIs, typically act by interrupting the viral replication cycle, whereas antibiotics directly eliminate and reduce the causative pathogen ([@B68]). Therefore, the common practice of infecting ferrets with a high viral inoculum could overwhelm the host (ferret) with an unrealistically large number of infectious viral particles and under such experimental conditions, the effectiveness of an antiviral treatment could be undermined as the antivirals would not be able to contain such rapid onset of viral infection. As demonstrated by [@B65], oseltamivir treatment significantly lowered viral shedding, lowered inflammatory nasal cell count and improved activity levels following a 10^2^ PFU/animal dose of infection, but had no significant effect on these parameters when a high viral inoculum of 10^6^ PFU/animal was used ([@B65]). Therefore, in the context of antiviral testing in ferrets and in particular to intranasal inoculation, careful consideration should be given to the amount of virus used, to prevent undermining the effectiveness of antivirals in influenza infection.

Drug Administration
===================

Administration of therapeutics into animals requires the careful consideration of many factors including the drug pharmacology, concentration, volume, timing, frequency of dose and route of administration ([@B103]). The antivirals for influenza treatment that are currently approved or in late-phase clinical trials in humans encompass various routes of administration including oral, inhaled and intravenous (**Table [2](#T2){ref-type="table"}**). Where possible the route of administration in animals should follow the same route of delivery as in humans so that the results can be better extrapolated to the findings in man ([@B102]; **Table [2](#T2){ref-type="table"}**).

###### 

The differences in antiviral drug administration route between human and animal model of influenza infection.

  Drugs         Approved administration route in human   Typical administration route used in animal studies   Reference                        
  ------------- ---------------------------------------- ----------------------------------------------------- -------------------------------- -----------------------------------------------
  Amantadine    Oral                                     Intraperitoneal                                       Oral                             [@B33]; [@B2]; [@B92]
  Rimantadine   Oral                                     NR                                                    Oral                             [@B92]
  Oseltamivir   Oral                                     Oral                                                  Oral                             [@B25]; [@B65]; [@B79], [@B78]; [@B6]; [@B64]
  Zanamivir     Powder inhalation                        Intranasal (L)                                        Intranasal (L)/Intraperitoneal   [@B33]; [@B38]; [@B92],[@B93]
  Laninamivir   Powder inhalation                        Intranasal (L)/Intratracheal (P)                      Intranasal (L)                   [@B51]; [@B80]
  Peramivir     Intravenous                              Intravenous                                           Intravenous/Intramuscular/Oral   [@B109]; [@B2]; [@B46]; [@B92]
  T-705         Oral                                     NR                                                    Oral                             [@B45]
  DAS181^a^     Powder inhalation                        NR                                                    Intranasal (L)                   [@B63]

a

Investigational drug; NR, Not reported; L, Liquid; P, Powder.

The delivery of parenterally administered antivirals, such as peramivir, in ferrets is relatively straight-forward and can be easily administered by intravenous injection ([@B109]; [@B46]). Administering drugs via the enteral (oral) route in ferrets can be limited by many factors such as the requirement for multiple dosing regimens, poor drug solubility and palatability of the drug to animals. In ferrets, direct feeding of orally administered compounds is preferred over oral gavage (which is commonly used in mice) as it does not require anesthesia, which can impact on the animal's health and behavior if given repeatedly, such as twice daily for 5 days. For oseltamivir administration, ferrets can be fed oseltamivir phosphate dissolved in sugar solution to achieve an accurate dosing ([@B79], [@B78]). The drug in sugar solution is well-tolerated by ferrets allowing multiple dosing without the need for sedation, although higher doses of the drug (e.g., 25 mg/kg) are less readily swallowed than the standard 5 mg/kg dose. In contrast, oral antivirals with poor solubility, such as nitazoxanide ([@B28]; [@B88]), pose difficulties when administering to ferrets, and therefore alternative methods, such as spiking the drug into food or in special 'treats', may be necessary ([@B102]).

The delivery of inhaled drugs, such as zanamivir and laninamivir, to ferrets poses additional challenges. Both zanamivir and laninamivir are delivered to humans as a dry powder formulation that is actively inhaled by the patient via specially designed inhalers ([@B15]). Mimicking this type of administration in animals is difficult, and is presumably why the majority of animal studies investigating zanamivir ([@B33]; [@B38]; [@B92],[@B93]) and laninamivir ([@B51]) have dissolved the compounds in saline or water and administered intranasally (**Table [2](#T2){ref-type="table"}**). While intranasal instillation of drugs is a simple technique that can be easily adopted by most laboratories, the relevance of delivering the drug in this manner when it is designed to be inhaled is questionable ([@B102]). In addition, it has been demonstrated in mice that intranasal instillation of drug administration can exacerbate viral infection leading to lower drug effectiveness ([@B93]). Insuﬄators are devices that have been widely used as a non-invasive method to administer powdered drugs for drug deposition studies in small animals such as mice or rats ([@B73]), but have been less commonly used in larger animals such as ferrets. To bridge this unmet need for a delivery system for powdered antivirals such as laninamivir, we recently characterized the usage of a dry powder insuﬄator to deliver laninamivir octanoate (LO) to ferrets prior to influenza infection ([@B80]). *In vitro* laser diffraction analysis showed that ∼80% LO together with its lactose carrier can be effectively discharged from the device and intratracheal administration of LO in anesthetized ferrets can be easily performed ([@B80]). For LO where a single dose is sufficient, the method is highly applicable, but repeated dosing would be difficult due to the need for regular anesthesia. The use of the insuﬄator device may be useful to investigate other inhaled drugs in ferrets, such as DAS181.

Drug Dosage
===========

Besides route of administration, accurate evaluation of the effectiveness of antivirals in animals is also dependent on the dose of drug being administered. In humans, the optimal dose is determined by pharmacokinetic/pharmacodynamic (PK/PD) analysis. The PK/PD of influenza antivirals is often determined during pre-clinical testing in animals by pharmaceutical companies ([@B103]), but data from these studies is often not in the public domain. For example, the majority of studies have used 5 mg/kg oseltamivir phosphate in ferrets as being 'equivalent' to the 75 mg dose in humans, although limited publicly available PK/PD data is available to support this ([@B54]; [@B69]; [@B84]). At the time of writing this review, we have found only a small number of PK studies of the influenza antivirals in animals such as mice, rats, and ferrets (**Table [3](#T3){ref-type="table"}**). As the generation and analysis of PK/PD data can involve a large number of animals and requires specialized modeling expertise, it is not always a viable option for research laboratories to complete such studies. Therefore, if PK/PD data of approved drugs in ferrets or other animals was made publicly available in open access databases, then this would greatly assist and encourage the use of a consensus dose in an animal to allow a better assessment and comparison of the effectiveness of the drugs across different studies.

###### 

Pharmacokinetics reports of different influenza antivirals in mice, rats, and ferrets.

  Drugs         Mice/Rats        Ferrets
  ------------- ---------------- ----------------
  Amantadine    NR               NR
  Rimantadine   [@B34]           NR
  Oseltamivir   [@B54]           [@B54]; [@B84]
  Zanamivir     [@B54]           NR
  Laninamivir   [@B49], [@B48]   NR
  Peramivir     [@B47]           [@B46]
  T-705         NR               NR
  DAS181        NR               NR

NR, Not reported.

Parameters to Assess the Effectiveness of Antiviral Treatment
=============================================================

Pathology
---------

One advantage of using the ferret is the ability to track viral shedding kinetics from both the upper and/or lower respiratory tract via nasal washing or lower bronchoalveolar lavage (BAL), although the latter is rarely used ([@B52]). In addition, ferrets can be monitored for clinical symptoms associated with human influenza infections including weight loss, rise in body temperature, sneezing, nasal discharge, and lethargy (**Table [4](#T4){ref-type="table"}**). Whilst weight, temperature and symptoms such as sneezing and nasal discharge can be easily assessed, lethargy is more challenging to quantitate accurately. Conventionally, the activity of ferrets has been determined by visually assessing movement of the animal and assigning an arbitrary score ([@B85]; [@B25]; [@B44]; [@B96]; [@B65]; [@B79]). However, we have recently reported on the use of video-tracking methodology, which allows the activity level of ferrets to be quantitated by computer software analysis ([@B78]). Not only did video-tracking improve the sensitivity of detecting activity changes post-infection, it also enabled the assessment process to be simplified and less prone to bias. To date, many studies including ours have shown that treatment with an antiviral, such as oseltamivir, can improve the activity level of ferrets infected with influenza ([@B25]; [@B65]; [@B79], [@B78]). This improved methodology allows a more accurate assessment and extrapolation of the associated effect of antivirals on activity or 'wellness'.

###### 

Different types of clinical and symptomatic parameters measured in influenza studies in ferrets.

  Parameters          Reference                                          
  ------------------- -------------------------------------------------- ---------------------------------------------------------------------------------
  Symptomatic         Sneezing                                           [@B37], [@B36]; [@B87]; [@B44]; [@B82]
                      Weight loss                                        [@B25]; [@B37], [@B36]; [@B44]; [@B104]; [@B65]; [@B79], [@B78]; [@B82]; [@B80]
                      Body temperature                                   [@B25]; [@B37]; [@B87]; [@B44]; [@B104]; [@B65]; [@B79], [@B78]; [@B80]
                      Activity (manual scoring)                          [@B25]; [@B37]; [@B44]; [@B65]; [@B79]
                      Activity (video-tracking)                          [@B78]
  Virological         Viral shedding kinetics^a,b,c^                     [@B25]; [@B36]; [@B44]; [@B104]; [@B65]; [@B79], [@B78]; [@B82]; [@B80]
  Histopathological   Lung histology                                     [@B12]; [@B89]; [@B37], [@B36]; [@B44]
  Inflammation        Total viable cell count^a^                         [@B25]; [@B65]; [@B79], [@B78]; [@B80]
                      Total protein concentration^a^                     [@B25]; [@B79], [@B78]; [@B80]
  Immunological       Differential cell count (innate immune cells)^c^   [@B44]
                      Influenza-specific antibodies                      [@B104]; [@B79], [@B78]; [@B80]
                      Hematology chemistry                               [@B96]
                      RNA expression (RT-PCR)                            [@B44]; [@B13], [@B14]; [@B82]
                      RNA expression (Microarray)                        [@B12]; [@B89]

a

Nasal wash;

b

Assay by TCID

50

, PFU or RT-PCR;

c

Bronchoalveolar lavage.

Immunology
----------

The major disadvantage of using ferrets as a model for studying influenza (or influenza antiviral effectiveness) is the lack of validated ferret-specific reagents, such as antibodies, to study the immunology of disease pathogenesis. However, because of the significant benefits of the model many laboratories are now attempting to validate cross-reactive antibodies and develop novel reagents for ferret research ([@B90]; [@B66]; [@B72]). One such collaborative effort is chaired by the United States Centre of Excellence for Influenza Research and Surveillance group at St. Jude Children's Research Hospital in Memphis, USA. To date, several groups have assessed ferret host immune responses to influenza infection based on RNA expression by either quantitative real-time PCR in either nasal washes, blood or lung ([@B58]; [@B13], [@B14]; [@B82]; [@B106]), or by using a canine microarray platform ([@B12]; [@B89]; **Table [4](#T4){ref-type="table"}**). Recently, the report of an annotated ferret transcriptome during influenza infection has also opened up an avenue for interrogating the global host gene expression to further understand host immunity toward influenza infection ([@B53]). In addition, simple immunological analysis such as measuring total cell count or protein concentration in nasal wash samples can also be useful as a determinant of inflammation ([@B24], [@B25]; [@B65]; [@B78]; [@B80]). Other basic immune measurements include differential staining of various leukocytes populations in the BAL or blood, and also clinical chemistry of different proteins in blood post influenza infection ([@B44]; [@B96]; **Table [4](#T4){ref-type="table"}**).

Despite a great effort to study the interplay between influenza infection and immunity in ferrets, the effect of antivirals on immunity in this model is still poorly understood. To date, the majority of the immunity-related studies on influenza antivirals have used mice as the animal model ([@B11]; [@B107]; [@B6]; [@B64]). Oseltamivir was found to reduce innate cell populations in BAL, such as neutrophils and macrophages, when given prophylactically, and reduced pro-inflammatory cytokines when given pre- and post-infection ([@B107]). In contrast, the effect of oseltamivir on the adaptive immune cell population, such as cytotoxic CD8^+^ T cells, is still unclear. While [@B11] reported that oseltamivir had minimal impact on the splenic population of T and B cells, and had no effect on the cytolytic activity of CD8^+^ T cells and natural killer cells in A(H1N1) influenza-infected mice ([@B11]), a recent study by [@B64], found oseltamivir reduced circulating and tissue-resident effector and memory CD8^+^ T cells in A(H1N1) influenza-infected mice and significantly reduced the protective effect in a subsequent infection episode ([@B64]). In addition, a study by [@B6] showed that although oseltamivir treatment reduced the number of CD8^+^ T cells in mice, they had normal recall responses and conferred protection against subsequent infection ([@B6]).

Future Directions for the Use of Ferrets to Assess Antiviral Effectiveness
==========================================================================

To date, the ferret remains as one of the preferred models for assessing influenza infection and as such has become an important model for antiviral testing. Although the ferret poses many advantages compared to other animal models, this review has highlighted some of the challenges of using the ferret to assess antiviral effectiveness. Researchers conducting studies in the ferret model of influenza infection need to consider progressing toward a more 'natural' infection methodology by either contact or non-contact transmission, or aerosol challenge, using drug doses that are based on PK/PD analysis and to deliver the drugs via a relevant route (**Figure [3](#F3){ref-type="fig"}**). The development of more robust parameters to measure antiviral effectiveness in ferrets, such as computational analysis of behavior/activity and the development of ferret-specific reagents to explore the immunological effects of antiviral treatment, will both greatly improve our understanding of antiviral modes of action and the effect on viral pathogenesis. In our opinion, the application of ferrets in antiviral studies should not be limited to just understanding therapeutic effectiveness. Instead, the ferret model can be applied to address other questions such as the *in vivo* effectiveness of antivirals against drug 'resistant' viruses, and the effectiveness of different antiviral treatment or prophylaxis strategies on preventing or minimizing transmission. Therefore, we anticipate that with continuous development and refinement of the ferret model for influenza antiviral testing, it has the potential to provide more meaningful data to better inform human use of influenza antivirals.
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